The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Regorafenib + nivolumab in MMR proficient advanced CRC

Name: Regorafenib + nivolumab in MMR proficient advanced CRC
Uploaded: 2020-07-03T15:33:53Z
Duration: 4 min 47 s
Description: Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Richard D. Kim • 3 Jul 2020

ESMO WCGIC 2020

Colorectal Cancer Gastrointestinal Cancer Antibodies Nivolumab Regorafenib

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).